Hodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines
نویسندگان
چکیده
منابع مشابه
Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines.
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer provide multidisciplinary recommendations for the clinical management of patients with prostate cancer. These NCCN Guidelines Insights highlight notable recent updates. Abiraterone acetate is a first-in-class hormonal agent that represents a new standard of care for patients with metastatic castration-recurr...
متن کاملNCCN Hodgkin Disease/Lymphoma Panel Members
These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN. These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN. This manuscript is being updated to correspond with the newly updated algorithm. These guidelines are a statement of consensus of the authors regarding the...
متن کاملNCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.
These NCCN Guidelines Insights highlight the important updates/changes specific to the 2016 version of the NCCN Clinical Practice Guidelines in Oncology for Multiple Myeloma. These changes include updated recommendations to the overall management of multiple myeloma from diagnosis and staging to new treatment options.
متن کاملSmoking Cessation, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.
Cigarette smoking has been implicated in causing many cancers and cancer deaths. There is mounting evidence indicating that smoking negatively impacts cancer treatment efficacy and overall survival. The NCCN Guidelines for Smoking Cessation have been created to emphasize the importance of smoking cessation and establish an evidence-based standard of care in all patients with cancer. These guide...
متن کاملNCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017.
The prognosis for patients with newly diagnosed acute lymphoblastic leukemia (ALL) has improved with the use of more intensive chemotherapy regimens, tyrosine kinase inhibitors, targeted agents, and allogeneic hematopoietic cell transplantation. However, the management of relapsed or refractory (R/R) ALL remains challenging and prognosis is poor. The NCCN Guidelines for ALL provide recommendati...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the National Comprehensive Cancer Network
سال: 2012
ISSN: 1540-1405,1540-1413
DOI: 10.6004/jnccn.2012.0061